Trial Profile
Phase II trial of OSI-774 (erlotinib, Tarceva,) and capecitabine for patients with previously untreated metastatic colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Erlotinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 30 Nov 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jun 2007 New trial record.